Cevdet AYDIN, Bekir ÇAKIR, Abbas Ali TAM, Cafer KAYA, Reyhan ERSOY

Differentiated thyroid cancer in patients with prolactinoma

Background/aim: Increasing evidence is available about the role of prolactin in the development of various cancers. The purpose of this study is to evaluate the frequency of thyroid cancer in patients with prolactinoma followed at a single site. Materials and methods: The medical records of 182 patients diagnosed with prolactinoma were reviewed retrospectively. Serum prolactin, antithyroglobulin, antithyroid peroxidase antibody, thyroid-stimulating hormone, free T4, and free T3 values and pituitary gland magnetic resonance imaging and thyroid ultrasound reports were evaluated. Results: Forty-five (39.5%) patients were found to have a thyroid nodule (13 solitary, 32 multiple). Ten patients were administered a thyroidectomy, and differentiated thyroid cancer (DTC) was detected in 6 of these patients (6/114, 5.3%). One patient had lung metastasis. The control group consisted of 113 individuals (101 females, 12 males with a mean age of 32.1 ± 9.1). In the ultrasound reports, 28 of these individuals (24.8%) had a thyroid nodule (5 solitary, 23 multiple), and one individual (1/113, 0.8%) had DTC. Conclusion: When compared to the control group, thyroid volume and thyroid nodularity were significantly higher in patients with prolactinoma (P < 0.001, P = 0.018, respectively); however, no statistically significant difference existed for the incidence of thyroid cancer (P = 0.196).

PDF

___

1. Schlechte JA. Clinical practice. Prolactinoma. N Engl J Med 2003; 349: 2035-2041.
2. Orbach H, Shoenfeld Y. Hyperprolactinemia and autoimmune diseases. Autoimmun Rev 2007; 6: 537-542.
3. Ben-Jonathan N, Mershon JL, Allen DL, Steinmetz RW. Extrapituitary prolactin: distribution, regulation, functions, and clinical aspects. Endocr Rev 1996; 17: 639-669.
4. Marano RJ, Ben-Jonathan N. Minireview: extrapituitary prolactin: an update on the distribution, regulation, and functions. Mol Endocrinol 2014; 28: 622-633.
5. Lopez-Pulido El, Muñoz-Valle JF, Del Toro-Arreola S, Luis F, Jave-Suárez LF, Bueno-Topete MR, Estrada-Chávez C, PereiraSuárez AL. High expression of prolactin receptor is associated with cell survival in cervical cancer cells. Cancer Cell Int 2013; 13: 103.
6. Kedzia C, Lacroix L, Ameur N, Ragot T, Kelly PA, Caillou B, Binart N. Medullary thyroid carcinoma arises in the absence of prolactin signaling. Cancer Res 2005; 6: 8497-8503.
7. Bole-Feysot C, Goffin V, Edery M, Binart N, Kelly PA. Prolactin (PRL) and its receptor: actions, signal transduction pathways and phenotypes observed in PRL receptor knockout mice. Endocr Rev 1998; 19: 225-268.
8. Ben-Jonathan N, Liby K, McFarland M, Zinger M. Prolactin as an autocrine/paracrine growth factor in human cancer. Trends Endocrinol Metab 2002; 13: 245-250.
9. Barkan AL, Stred SE, Reno K, Markovs M, Hopwood NJ, Kelch RP, Beitins IZ. Increased growth hormone pulse frequency in acromegaly. J Clin Endocrinol Metab 1989; 69: 1225-1233.
10. Berinder K, Akre O, Granath F, Hulting AL. Cancer risk in hyperprolactinemia patients: a population-based cohort study. Eur J Endocrinol 2011; 165: 209-215.
11. Fernandez I, Touraine P, Goffin V. Prolactin and human tumourogenesis. J. Neuroendocrinol 2010; 22: 771-777.
12. Goffin V, Bernichtein S, Touraine P, Kelly PA. Development and potential clinical uses of human prolactin receptor antagonists. Endocr Rev 2005; 26: 400-422.
13. Dekkers OM, Romijn JA, de Boer A, Vandenbroucke JP. The risk for breast cancer is not evidently increased in women with prolactinemia. Pituitary 2010; 13: 195-198.
14. Bernichtein S, Touraine P, Goffin V. New concepts in prolactin biology. J Endocrinol 2010; 206: 1-11.
15. Crepin A, Bidaux G, Abeele F Vanden, Dewailly E, Goffin V, Prevarskaya N, Slomianny C. Prolactin stimulates prostate cell proliferation by increasing endoplasmic reticulum content due to SERCA 2b over-expression. Biochem J 2007; 401: 49-55.
16. Harris J, Stanford PM, Oakes SR, Ormandy CJ. Prolactin and the prolactin receptor: new targets of an old hormone. Ann Med 2004; 36: 414-425.
17. Lu CC, Tsai SC, Huang WJ, Tsai CL, Wang PS. Effects of hyperprolactinemia on calcitonin secretion in male rats. Metabolism 1999; 48: 221-226.
18. Costa P, Catarino AL, Silva F, Sobrinho LG, Bugalho MJ. Expression of prolactin receptor and prolactin in normal and malignant thyroid: a tissue microarray study. Endocr Pathol 2006; 17: 377-386.
19. Bhatavdekar JM, Patel DD, Chikhlikar PR, Shah NG, Vora HH, Ghosh N, Trivedi TI. Ectopic production of prolactin by colorectal adenocarcinoma. Dis Colon Rectum 2001; 44: 119- 127.
20. Soroush AR, Zadeh HM, Moemeni M, Shakiba B, Elmi S. Plasma prolactin in patients with colorectal cancer. BMC Cancer 2004; 4: 97.
21. Yeh YT, Lee KT, Tsai CJ, Chen YJ, Wang SN. Prolactin promotes hepatocellular carcinoma through Janus kinase 2. World J Surg 2012; 36: 1128-1135.
22. González-Lucano LR, Muñoz-Valle JF, Ascencio-Cedillo R, Domínguez-Rosales JA, López-Rincón G, Del Toro-Arreola S, Bueno-Topete M, Daneri-Navarro A, Estrada-Chávez C, Pereira-Suárez AL. Increased expression of the prolactin receptor is associated with malignant laryngeal tumors. Exp Ther Med 2012; 3: 603-607.
23. Bhatavdekar JM, Patel DD, Vora HH, Shah NG, Chikhlikar PR, Ghosh N. Prolactin as a local growth promoter in patients with locally advanced tongue cancer: GCRI experience. Head Neck 2000; 22: 257-264.
24. Levina VV, Nolen B, Su Y, Godwin AK, Fishman D, Liu J, Mor G, Maxwell LG, Herberman RB, Szczepanski MJ et al. Biological significance of prolactin in gynecologic cancers. Cancer Res 2009; 69: 5226-5233.
25. Sayki Arslan M, Sahin M, Topaloglu O, Tutal E, Karakose M, Gungunes A, Cakal E, Ozbek M, Delibasi T. Hyperprolactinaemia associated with increased thyroid volume and autoimmune thyroiditis in patients with prolactinoma. Clin Endocrinol 2013; 79: 882-886.
26. Freeman ME, Kanyicska B, Lerant A, Nagy G. PRL: structure, function, and regulation of secretion. Physiol Rev 2000; 80: 1523-1631.
27. Rui H, Kirken RA, Farrar WL. Activation of receptor-associated tyrosine kinase JAK2 by prolactin. J Biol Chem 1994; 269: 5364-5368.
28. Tworoger SS, Eliassen AH, Rosner B, Sluss P, Hankinson SE. Plasma prolactin concentrations and risk of postmenopausal breast cancer. Cancer Res 2004; 64: 6814-6819.
29. Galsgaard ED, Rasmussen BB, Folkesson CG, Rasmussen LM, Berchtold MW, Christensen L, Panina S. Re-evaluation of the prolactin receptor expression in human breast cancer. J Endocrinol 2009; 10: 115-128.
30. Sethi BK, Chanukya GV, Nagesh VS. Prolactin and cancer: has the orphan finally found a home? Indian J Endocrinol Metab 2012; 16: S195-S198.